Aptus Capital Advisors, LLC Xilio Therapeutics, Inc. Transaction History
Aptus Capital Advisors, LLC
- $8.97 Billion
- Q1 2025
A detailed history of Aptus Capital Advisors, LLC transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Aptus Capital Advisors, LLC holds 46,000 shares of XLO stock, worth $41,400. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,000
Previous 41,000
12.2%
Holding current value
$41,400
Previous $39,000
15.38%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding XLO
# of Institutions
34Shares Held
11.1MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$4.11 Million1.1% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.3 Million16.6% of portfolio
-
Morgan Stanley New York, NY1.16MShares$1.04 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.14MShares$1.02 Million0.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5668KShares$600,9670.57% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $24.7M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...